date:Apr 27, 2016
DSM has reported a one percent year-on-year uplift in sales Q1 to 1.9 billion ($2.14 billion) helped by demand for food enzymes.
The worlds largest vitamin maker reported that EBITDA (earnings before interest, tax, depreciation and amortisation) was up 19 percent to 296 million ($334 million) in Q1.
Feike Sijbesma, chief executive of DSM, said: We are pleased to report that we delivered a strong first quarter in terms of growth profitability and returns, with all businesses seeing the effects